2026 Mushroom Wellness Transparency Report & 101-Entry Audit

Media-ready assets now available.Journalists, newsletter editors, directories, educators, and podcast researchers can use the Media Hub for the citation block, branded PDFs, transparent logo file, 10-question checklist, scoring rubric, infographic, and approved short summaries.

Education-only orientation. This report is not medical advice, legal advice, a product endorsement, a safety certification, or a clinical evaluation. It does not rank brands for purchase. It evaluates the transparency of publicly visible product page information only — what a consumer can see before making a decision.

What this page does and does not contain. This page discusses labeling, testing visibility, ingredient disclosure, claim restraint, and public-facing safety language. It does not evaluate product effectiveness, recommend products, verify product contents, or make legal conclusions about any brand.

Cluster eCommerce disclosure. iMicrodosing.com — the eCommerce site operated by the same cluster that publishes this report — is included as entry #101. It is scored on the full 100-point standard rubric with no adjustments and no N/A dimensions. No special treatment in either direction. iMicrodosing.com scored 80/100 Grade B. See the Brand Audit for the full evidenced scorecard.

Part I — Why This Report Exists

The mushroom wellness category is no longer a small, clearly defined market. A consumer searching online in 2026 encounters functional mushroom supplements, mushroom gummies, nootropic blends, Amanita muscaria products, and products that imply psilocybin-related effects — all using overlapping language, similar visual branding, and comparable wellness claims.

Federal agencies have warned consumers about mushroom-containing products linked to severe adverse events including seizures, hospitalization, and loss of consciousness. [1] Government Investigation of Illnesses: Diamond Shruumz-Brand Chocolate Bars, Cones, & Gummies (June 2024) U.S. Food and Drug Administration (2024) Link → The FDA issued a warning letter in 2025 about Amanita muscaria dietary supplements being adulterated under federal law. [2] Government FDA Warning Letter to Blue Forest Farms re: Amanita muscaria dietary supplements U.S. Food and Drug Administration (2025) Link → FTC guidance for health products requires advertising claims to be truthful, not misleading, and scientifically substantiated. [3] Government Health Products Compliance Guidance Federal Trade Commission (2022) Link → A 2026 RAND report estimated that millions of U.S. adults had microdosed psychedelics in the past year. [4] Institutional U.S. Psychedelic Use and Microdosing in 2025: Insights from a Probability-Based and Nationally Representative Survey RAND Corporation (2026) Link →

Consumer interest is rising at exactly the moment disclosure quality most needs to keep pace.

The core principle of this report:

A consumer should be able to understand what a mushroom product is, what it contains, what evidence supports its claims, what risks may apply, and how to verify the company’s transparency — before making any decision.

Part II — The Consumer Transparency Standard

The 100-Point Scoring Framework

Each brand is evaluated across ten dimensions, each scored 0–10. Maximum total: 100 points.

Transparency Grades

Part III — Verified Batch Findings

The full interactive scorecard with per-brand evidence is in the Brand Audit article. What follows is the Batch 1 executive summary.

Finding 1 — COA visibility is the sharpest dividing line. Real Mushrooms (9/10), FreshCap (8/10), and Lifecykel (8/10) all link batch-specific, accredited third-party COAs from product pages. Host Defense (4/10), MUD\WTR (4/10), and Om Mushroom (5/10) have no publicly accessible batch COA confirmed.

Finding 2 — On-site lab ≠ independent third-party COA. Gaia Herbs (8) has an on-site ISO-certified laboratory — rigorous but internal. It scored 6/10 on COA Visibility despite 9/10 ingredient transparency. A brand testing its own products in its own facility cannot provide the same verification as a named accredited third-party.

Finding 3 — Proprietary blends are a confirmed transparency failure. Four Sigmatic refused to disclose L-theanine amount citing “competitive edge” — confirmed in a company Trustpilot response. Onnit’s Shroom Tech uses proprietary blends throughout all products — confirmed by multiple independent sources. Both brands scored lower in Ingredient Transparency and Dosage Clarity as a result.

Finding 4 — MUD\WTR has the worst support and refund record in Batch 1. Email-only contact, no phone, no live chat. Trustpilot (May 2026) confirms cancelled orders charged for 2+ weeks without refund. Subscription cancellation described as “nearly impossible” by multiple customers who required credit card disputes. Support: 4/10. Refund: 4/10 — lowest in both dimensions across the entire verified set.

Finding 5 — Facility certification is not a substitute for batch COA. Om Mushroom (5) has BRCGS AA Audit Rating — a facility-level certification. This is not a batch-specific COA accessible to consumers before purchase. These are distinct things; conflating them is a common transparency gap.

Finding 6 — iMicrodosing.com is the highest-scoring psilocybin-adjacent brand in the audit at 80/100. Verified through live page fetches and client-provided COA screenshots from Rose City Laboratories (ANAB/ILAC-MRA). Highest dimensions: Medical Claim Restraint (9/10 — zero disease-treatment claims on commerce pages), Shipping Transparency (9/10 — best-in-audit dedicated page), Support Availability (9/10 — named leadership, live Chatra, 24/7, free consultations). Lowest: Legal Disclaimers (7/10 — legal context handled by .net cluster property, not surfaced on commerce pages directly).

Batch 2 (functional supplements 11–20) — verified June 2026 — consumer average 50/100 Grade D.

Batch 2 key findings. No public COA in 8 of 9 consumer brands. Two new mycelium-on-grain confirmations: Nordic Naturals (“organic myceliated oats”) and Solaray (“Mycelium/Organic Whole Oat Biomass” for all 8 mushroom species). Three proprietary blends confirmed: NutriFlair (2600mg total, no per-species), Ancient Nutrition (1g “Organic Multi Mushroom Immune Blend”), RYZE (Super6™). NutriFlair support confirmed inaccessible via June 2026 Trustpilot reviews. Nammex (Brand 17) scored 80/100 Grade B in B2B supplier context only — not included in consumer average.

Batch 3 (functional supplements 31–40) — verified June 2026 — consumer average 49/100 Grade D.

Batch 3 key findings. Two domain corrections required: Myco CLINIC’s correct domain is myco-clinic.com (hyphenated), and Ritual Superfoods’ listed domain (ritualsuperfoods.com) did not match any live brand — the correct match is Rritual Superfoods at rritual.com. A new mycelium-on-grain confirmation: Rritual (“we grow in organic whole oats and brown rice,” confirmed directly from the brand’s own FAQ). NOW Cordyceps confirmed to use mycelium, not fruiting body, via ingredient label. Two proprietary blends confirmed: CBDfx Microdose Mushroom Gummies and Goomz (“Plant Based Proprietary Mushroom Blend,” confirmed directly from the brand’s own FAQ); Mushgooms’ proprietary blend confirmed by an independent reviewer. Goomz scored lowest in the batch (32/100) on a combination of no confirmed third-party testing, a proprietary blend, and marketing language (“euphoric rush,” “mind expansion,” guaranteed effects in “exactly 45 minutes”) that extends well beyond standard DSHEA structure/function bounds for a non-psychoactive functional product. Myco CLINIC (Brand 33) scored 43/100 Grade F in B2B/practitioner-channel context only — not included in consumer average, the same treatment applied to Nammex in Batch 2. Natural Stacks’ originally catalogued product had been discontinued; the live product (Smart Lion’s Mane™) was confirmed via direct page fetch to be genuinely fruiting-body-only and Nammex-sourced, but the brand’s independent review footprint (12 Trustpilot reviews, not BBB accredited) remains very thin.

Batch 3b (functional supplements 21–30) — verified June 2026 — average 41/100 Grade D.

Batch 3b key findings. This is the lowest batch average recorded in the audit so far, and the first batch in which no brand publishes a public, batch-specific, product-page-linked COA. Four domain corrections required: Peak State’s correct domain is peakstatecoffee.com, not drinkpeakstate.com; Alice Mushroom’s correct domain is alicemushrooms.com (plural), not alicemushroom.com; Mojo’s correct domain is mojo.shop, not mojomushrooms.com; Troomy Nootropics’ correct domain is troomy.com, not troomynootropics.com. Two proprietary blends confirmed: SuperMush (523mg blend, no per-species mg despite naming specific extraction ratios) and Mojo (356mg functional + 224mg nootropic blend). Peak State’s own site contradicts itself on fruiting body vs. mycelium between its homepage and its sample-request page. North Spore stood out for an explicit, unambiguous “100% fruiting bodies and sclerotia” claim — one of the clearest positive statements found anywhere in this audit — though it still lacks a public third-party COA. Documented support/refund failures: Mojo (non-consensual subscription billing, customer required to pay international return shipping) and SuperMush (refund denial pending a doctor’s note not disclosed in any published policy). Every brand in this batch fell far below the 500-review Trustpilot threshold; the highest was Alice Mushroom at 70 reviews.

Batch 4 (Amanita/Muscimol 41–50) — verified June 2026 — average 51/100 Grade D.

Batch 4 key findings. This is the first batch of the Amanita/Muscimol category, and it surfaces a transparency problem distinct from prior batches: three of ten brands (Area 52, BudPop, Royal CBD) market products under Amanita-muscaria branding or category pages whose current flagship product, per its own on-site description, discloses no Amanita extract or muscimol content at all — most likely downstream of FDA pressure on Amanita+THC combination products, as one BudPop customer review put it, “the FDA said no to that.” One domain correction was required: Elyxr’s correct domain is elyxr.com, not elyxr.la. Hometown Hero led the batch at 64/100 Grade C — the first Amanita-category brand in this audit to publish lot-numbered, per-batch COA links directly on its product pages, alongside a named CEO and explicit pregnancy/liver-disease/alcohol contraindications. Royal CBD scored lowest at 42/100 Grade F, the most severe instance of the Amanita-in-name-only pattern: its “Mushroom+” product page lists six botanical and adaptogen ingredients with no mention of Amanita muscaria or muscimol whatsoever. Elyxr’s product listed muscarine — a toxic compound distinct from muscimol — as an “active ingredient” with no explanation, an unusual and unexplained disclosure choice. Review-volume thinness continued from prior batches: only Exhale Wellness (8,651+) and Cheef Botanicals (2,700+) cleared the 500-review Trustpilot threshold; four of ten brands had fewer than 200 reviews.

Batch 5 (Amanita/Muscimol 51–60) — verified June 2026 — average 47.5/100 Grade F.

Batch 5 key findings. This is the lowest full-batch average recorded in the audit so far. Blue Forest Farms is the subject of an active FDA Warning Letter (September 2025) formally determining its Amanita Muscaria Microdose Capsules, Magic Potion Tincture, and Magic Chocolate adulterated under the Federal Food, Drug, and Cosmetic Act, citing documented risk of delirium, seizures, coma, respiratory depression, and death — the most severe legal-disclosure failure identified anywhere in this audit, and the products remain listed for sale. STNR Creations separately received an FDA warning letter (July 2025) for its Delta-8/Delta-9 gummy line as an unsafe food additive — not the Amanita product itself, but a serious company-wide regulatory signal. Four brands originally catalogued in this batch (MushroomsPlanet, Amanita Dream, Terp Boys Amanita, Vida Optima Amanita) could not be verified as real Amanita-selling entities — in three cases the catalogued domain belongs to a brand confirmed to sell no Amanita product at all, and in the fourth the domain does not resolve to any commercial entity — and were replaced with independently verified substitutes: VidaCap, King B Distribution, Elevate, and Mamanita. Premium Jane led the batch at 68/100 Grade C on a batch-specific COA linked directly on the product page and named active ingredients. Mamanita scored lowest at 22/100 Grade F — the weakest transparency finding in the audit to date — with no COA, no clear Amanita/muscimol disclosure on its own domain, and no independent review-platform footprint. Review-volume thinness was severe across the batch: only Binoid (~1,090), Premium Jane (2,300+), and VidaCap (608, on Reviews.io) cleared the 500-review threshold; STNR Creations and JustKana had 1 and ~40 reviews respectively.

Batch 6 (Amanita/Muscimol 61–70) — verified June 2026 — average 43.7/100 Grade F.

Batch 6 key findings. This is the lowest full-batch average recorded in the audit to date, and the most severe brand-cataloguing failure encountered so far: of the 13 originally catalogued brands, 12 could not be verified as real Amanita-selling entities via direct fetch of their own primary domains. Two (Secret Nature, Mellow Fellow) carried only an identical, templated “we do not ship amanita muscaria to Louisiana” legal-boilerplate disclaimer shared across many unrelated hemp storefronts — not actual evidence of an Amanita product — while their own site navigation contained no mushroom or Amanita category whatsoever. One substitute candidate (Exodus, exoduscbd.com) was found to have had its domain fully hijacked by an unrelated overseas gambling-spam operation. Ten brands were independently verified as real and substituted in; this batch closes at 10 of the planned 13 brands, with the remaining 3 Amanita/Muscimol slots deferred to a future session. Standard CBD and Colorado Hemp Honey tied for the batch lead at 56 and 54/100 respectively; four brands (Dozo, Moon and Silo, Trippy Extrax, Viva La Shroom) tied lowest at 33/100. A new and severe ingredient-transparency pattern emerged: in 6 of 10 brands, Amanita is sold only as one ingredient among four to six psychoactive compounds in a single blended product (e.g. THCA + Amanita + THCP + Delta-8 + Delta-10), making it impossible for a consumer to isolate Amanita’s specific contribution to any disclosed effect — a more severe version of the proprietary-blend pattern first noted in functional-supplement batches. Three brands (Dozo, Road Trip, Exodus, Wunder) were also found to operate across multiple, inconsistently branded domains for the same product line, a domain-fragmentation transparency concern distinct from a simple wrong-domain correction.

Batch 7 (Psilocybin-Adjacent/Nootropic 71–80) — verified June 2026 — average 49.6/100 Grade D.

Batch 7 key findings. This batch closed the three Amanita/Muscimol slots deferred from Batch 6 (71–73: Milagro Mushrooms, JustKana, Hometown Hero) and opened the Psilocybin-Adjacent/Nootropic category with its first seven slots (74–80). Hometown Hero and BudPop/Functional Lyfe (tied at 60) lead the batch; Milagro Mushrooms scored lowest at 37/100 on a COA mismatched to the wrong product line and a checkout subscription-authorization pattern consistent with the non-consensual-billing concern first flagged in Batches 5–6. Five of the ten originally catalogued brands failed verification and required substitution. Diamond Shruumz’s site is now inactive, reflecting its 2024 nationwide FDA recall following 180+ illnesses, 73 hospitalizations, and 3 potentially associated deaths. [1] Government Investigation of Illnesses: Diamond Shruumz-Brand Chocolate Bars, Cones, & Gummies (June 2024) U.S. Food and Drug Administration (2024) Link → Polkadot and One Up each had five-plus and seven-plus competing “official” domains respectively, with active scam reports attached — an escalation of the multi-domain fragmentation pattern into full brand-name squatting at scale, where no single legitimate domain owner could be identified at all. Neau Tropics’ catalogued domain was a gated, productless stub, while several other domains under the same brand name openly advertised psilocybin-infused (federally illegal) products. SHRUUM/CannaAid required a domain correction to a verified real company, but that company’s current catalog had no live Amanita category. Separately, Mushroom Lyfe (rebranded Functional Lyfe) was found to have been specifically named in the CDC’s 2024 national MMWR outbreak investigation into severe illness from mushroom-containing chocolate products — the same investigation that covered Diamond Shruumz — but has since fully exited the psychoactive product category, a documented case of a brand surviving regulatory scrutiny by changing its product line rather than ceasing operations. [5] Government Severe Illness Associated with Eating Mushroom-Containing Chocolate Products — United States, January–October 2024 U.S. Centers for Disease Control and Prevention (2026) Link →

Batch 8 (Psilocybin-Adjacent/Nootropic 81–90) — verified June 30, 2026 — average 48.0/100 Grade F.

Batch 8 key findings. Seven of the ten originally catalogued brands required correction or substitution — the most severe cataloguing-failure rate recorded in this audit to date, surpassing Batch 6 and Batch 7. MoonWlkr leads the batch at 71/100, the strongest brand identified across Batches 7–8, with a named parent company (Upexi, Inc.), business phone number, 30-day returns, and per-batch QR-linked COAs. Silly Dots scored lowest at 37/100 after its shipping and refund policies could not be located despite a direct search. Two new cataloguing-failure patterns emerged this batch: Moonwalkr Mushroom’s catalogued domain (moonwalkr.in) resolved to an entirely unrelated Indian cricket-equipment company — the first “wrong-industry domain” error recorded in this audit — and was corrected to the real brand, MoonWlkr (moonwlkr.com). Separately, an initial substitute candidate for JITI Mushrooms, Moocah, was rejected after its own storefront was found to self-disclose a scam-impersonation warning and to have stopped accepting standard card payments in favor of cryptocurrency and peer-to-peer apps — a credibility pattern treated as disqualifying rather than documented-and-kept. Wonder, Stem + Mushroom, and Shrooms Online Co. all required substitution after their catalogued domains were confirmed unfindable, brand-squatted, or (in the case of Shrooms Online Co.) resolved to a Canadian seller of actual psilocybin, out of scope for this audit. Fungi Perfecti, while real and reputable, was confirmed via full site-navigation fetch to sell no psilocybin or microdosing product at all, requiring substitution to Clevr Blends after an initial candidate (Hixotic) was rejected for meeting the three-domain brand-squatting threshold.

Batch 9 (Psilocybin-Adjacent/Nootropic 91–100) — verified June 30, 2026 — average 55.7/100 Grade D. Final batch of the 101-entry audit.

Batch 9 key findings. Eight of the ten originally catalogued brands required full substitution and a ninth required a domain correction — the most severe cataloguing-failure rate recorded across the entire 101-entry audit, surpassing every prior batch including Batch 6 and Batch 8. Om Mushroom Superfood leads the batch and is the strongest brand identified in Batch 9, with named founders, a named California facility, named phone support, and a documented 30-day satisfaction guarantee. BudPop scored lowest at 44/100 after a weak category-fit finding: its core business is hemp/THCA cannabinoids, with its mushroom product line a minor side-offering. Two catalogued brands (MindMend and Euphoria Psychedelics) were confirmed to sell actual psilocybin product shipped from Canada, out of scope for this US-focused audit; an initial substitute candidate for MindMend, Golden Rule, was also rejected after direct fetch confirmed it too sells actual psilocybin product despite being US-based. A new pattern was identified and confirmed twice in this batch: the “application-gateway brand,” where a catalogued brand (Dose Therapy) explicitly states it sells no product directly and instead screens and routes customers to an undisclosed third-party seller via a paid consultation process — distinct from the simpler education-platform mismatch seen with Third Wave and Wayofleaf Nootropics in this same batch. Malabar Gold’s catalogued domain resolved to an unrelated international jewelry company — the second “wrong-industry domain” error recorded in this audit. Inner Atlas (US) and Spore Club were both confirmed unfindable as US entities. A further new pattern was flagged for Mindful Mushrooms: three small, unrelated businesses share the same generic brand name, one of which (mindfulmushrooms.co) uses a suspiciously near-identical product-naming convention to MindMend’s exact psilocybin lineup, applied instead to legal functional-mushroom ingredients — flagged for monitoring rather than treated as disqualifying. With Batch 9 complete, all 101 scored entries in this audit are now fully verified.

Part IV — iMicrodosing.com — Cluster eCommerce Entry

Why iMicrodosing.com Is Included

iMicrodosing.com is the eCommerce site operated by the same cluster that publishes this report. It sells psilocybin-containing capsules, gummies, chocolates, edibles, and whole mushrooms to US consumers. Including it in the audit creates an obligation to apply the same standard used for all other brands — rigorously, with no adjustments and no N/A dimensions. Excluding it would itself be a form of bias.

Scoring

iMicrodosing.com was scored on the full 100-point standard rubric applied to all other brands. All ten dimensions are applicable. The score is 80/100 Grade B.

Part V — The Consumer Checklist

Before trusting any mushroom wellness product page, a consumer should be able to answer all ten of the following questions directly from the public product page — without contacting the company, searching elsewhere, or making a purchase.

Affiliation and scoring disclosure. iMicrodosing.org is an education-focused property. iMicrodosing.com is an affiliated eCommerce property and is included in this audit for transparency. Its score was calculated using the same public-facing criteria applied to other entries. Inclusion does not turn this report into a product recommendation, safety certification, legal conclusion, or verification of product contents.

Part VI — Cluster Contents

Frequently Asked Questions

Corrections and updates. Scores reflect public-facing information available at the time of review. Brands may update labels, COAs, ingredient panels, legal disclosures, or claim language after publication. If a brand believes a score should be reviewed, it may request correction by identifying the specific public-facing page, document, or label language that changed.